Tag : ARCC

NEWS AND PERSPECTIVE

Nivolumab + ipilimumab demonstrates long-term survival benefits as a first-line treatment for patients with previously untreated advanced renal cell carcinoma
With a median follow-up of 99.1 months, the recent analysis of the CheckMate 214 trial serves as the longest reported follow-up for any phase 3 trial of a checkpoint inhibitor combination therapy in advanced renal cell carcinoma (aRCC), which demonstrated the remarkable and durable clinical responses of nivolumab + ipilimumab as a first-line therapy for untreated aRCC.